name: Isovaleric Acidemia
category: Mendelian
creation_date: '2025-06-12T20:16:27Z'
updated_date: '2026-02-28T02:52:12Z'
classifications:
  harrisons_chapter:
  - classification_value: hereditary disease
synonyms:
- Isovaleric aciduria
- IVA
- Isovaleryl-CoA dehydrogenase deficiency
- IVD deficiency
description: 'Isovaleric acidemia (IVA; OMIM 243500) is an autosomal recessive inborn error of leucine catabolism caused by
  deficiency of the mitochondrial enzyme isovaleryl-CoA dehydrogenase (IVD). IVD catalyzes the conversion of isovaleryl-CoA
  to 3-methylcrotonyl-CoA; its deficiency leads to accumulation of isovaleric acid, 3-hydroxyisovaleric acid, isovalerylcarnitine
  (C5), and isovalerylglycine in body fluids. The clinical spectrum ranges from severe neonatal-onset metabolic crises with
  ketoacidosis, hyperammonemia, and encephalopathy to attenuated biochemical-only phenotypes detected by newborn screening.
  Treatment consists of leucine-restricted diet, carnitine and glycine supplementation, and emergency management during catabolic
  episodes. Secondary hyperammonemia results from inhibition of N-acetylglutamate synthase (NAGS) by isovaleryl-CoA.

  '
disease_term:
  preferred_term: isovaleric acidemia
  term:
    id: MONDO:0009475
    label: isovaleric acidemia
parents:
- Organic Acidemia
- Inborn Error of Metabolism
pathophysiology:
- name: IVD molecular function deficiency
  description: 'Biallelic pathogenic variants in IVD reduce isovaleryl-CoA dehydrogenase
    catalytic activity in mitochondria.

    '
  genes:
  - preferred_term: IVD
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency of isovaleryl-CoA dehydrogenase (IVD), leading to an accumulation of isovaleric acid and its derivates 3-hydroxyisovaleric acid, isovaleryl (C5)-carnitine and isovalerylglycine in body fluids.
    explanation: Supports IVD molecular dysfunction as the initiating defect.
  downstream:
  - target: Deficient leucine catabolic flux
    description: Reduced IVD activity blocks isovaleryl-CoA oxidation in leucine catabolism.
- name: Deficient leucine catabolic flux
  description: 'IVD deficiency blocks leucine degradation at the mitochondrial isovaleryl-CoA
    to 3-methylcrotonyl-CoA step, causing upstream accumulation of isovaleryl-CoA,
    isovaleric acid, and characteristic secondary metabolites.

    '
  biological_processes:
  - preferred_term: branched-chain amino acid catabolic process
    term:
      id: GO:0009083
      label: branched-chain amino acid catabolic process
  - preferred_term: leucine catabolic process
    term:
      id: GO:0006552
      label: leucine catabolic process
  evidence:
  - reference: PMID:30740403
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Organic acids (OAs) are intermediary products of several amino acid catabolism or degradation via multiple biochemical
      pathways for energy production.
    explanation: Supports organic acid disorders as defects in amino acid catabolic pathways.
  downstream:
  - target: Secondary urea cycle impairment and hyperammonemia
  - target: Mitochondrial energy depletion and oxidative stress
  - target: Neuronal membrane dysfunction via Na+,K+-ATPase inhibition
- name: Secondary urea cycle impairment and hyperammonemia
  description: 'Isovaleryl-CoA inhibits N-acetylglutamate synthase (NAGS), reducing N-acetylglutamate availability and impairing
    activation of carbamoyl phosphate synthetase 1 (CPS1), the rate-limiting entry enzyme of the urea cycle. Combined with
    acetyl-CoA depletion, this produces secondary hyperammonemia that contributes to encephalopathy and neurological complications.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:30740403
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: High anion gap metabolic acidosis with hyperammonemia is a characteristic OA biochemical finding.
    explanation: Supports hyperammonemia as characteristic of organic acid disorders.
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The clinical presentation is highly variable, ranging from life-threatening metabolic crises with metabolic acidosis
      and hyperammonemia to a clinically asymptomatic only biochemical phenotype.
    explanation: Directly supports hyperammonemia as a key crisis feature of IVA.
- name: Mitochondrial energy depletion and oxidative stress
  description: 'Accumulated isovaleryl-CoA and isovaleric acid impair tricarboxylic acid cycle function, with evidence for
    inhibition of citrate synthase and reduced CO2 production from acetate in brain tissue. Chronic metabolite accumulation
    also increases oxidative stress, contributing to neurological morbidity. Oxidative stress from chronic persistent buildup
    of isovaleric acid may be more neurologically detrimental than acute buildup.

    '
  biological_processes:
  - preferred_term: tricarboxylic acid cycle
    term:
      id: GO:0006099
      label: tricarboxylic acid cycle
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:19210957
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: IVA administration significantly inhibited (14)CO(2) production from acetate (22%) and citrate synthase activity
      (20%) in cerebral cortex homogenates prepared 24 h after injection.
    explanation: Demonstrates TCA cycle impairment in cerebral cortex from isovaleric acid exposure in vivo.
  - reference: PMID:27613073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: More than 65 organic acidurias have been described
    explanation: Review providing pathogenetic basis for oxidative stress and mitochondrial dysfunction in classical organic
      acidurias including IVA.
- name: Neuronal membrane dysfunction via Na+,K+-ATPase inhibition
  description: 'Isovaleric acid directly inhibits Na+,K+-ATPase activity in cerebral cortex, a crucial enzyme for maintaining
    membrane potential and normal neurotransmission. This inhibition is observed as early as 2 hours after exposure and persists
    at 24 hours, contributing to the acute encephalopathy seen during metabolic crises.

    '
  biological_processes:
  - preferred_term: sodium ion transport
    term:
      id: GO:0006814
      label: sodium ion transport
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:19210957
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: IVA injection significantly inhibited Na(+),K(+)-ATPase activity (25%) in cerebral cortex of rats 2 or 24 h after
      IVA administration, while pre-treatment of rats with creatine completely prevented the inhibitory effects of IVA on
      Na(+),K(+)-ATPase.
    explanation: Demonstrates direct inhibition of Na+,K+-ATPase by isovaleric acid in cerebral cortex and prevention by creatine.
phenotypes:
- name: Metabolic acidosis
  frequency: VERY_FREQUENT
  description: 'High-anion-gap metabolic acidosis is the hallmark acute presentation during metabolic decompensation episodes.
    In a Jordanian cohort, acidosis was present in 81% of patients.

    '
  phenotype_term:
    preferred_term: Metabolic acidosis
    term:
      id: HP:0001942
      label: Metabolic acidosis
  evidence:
  - reference: PMID:38344522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Laboratory results showed acidosis (81%), hyperammonemia (71.4%), and hypoglycemia (14.3%).
    explanation: Directly quantifies acidosis at 81% in an IVA cohort.
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The clinical presentation is highly variable, ranging from life-threatening metabolic crises with metabolic acidosis
      and hyperammonemia to a clinically asymptomatic only biochemical phenotype.
    explanation: Supports metabolic acidosis as a key crisis phenotype.
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: 'Secondary hyperammonemia results from inhibition of N-acetylglutamate synthase by isovaleryl-CoA. In a Jordanian
    cohort, hyperammonemia was present in 71.4% of patients. Repeated hyperammonemic episodes increase the risk of brain damage.

    '
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:38344522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Laboratory results showed acidosis (81%), hyperammonemia (71.4%), and hypoglycemia (14.3%).
    explanation: Directly quantifies hyperammonemia at 71.4% in an IVA cohort.
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Repeated and frequent episodes of hyperammonaemia (alongside metabolic decompensations) can result in impaired
      growth and intellectual disability, the severity of which increase with longer duration of hyperammonaemia.
    explanation: Supports hyperammonemia as contributing to neurological sequelae.
- name: Vomiting
  frequency: FREQUENT
  description: 'Recurrent vomiting is the most prevalent symptom during metabolic crises in IVA. In a Jordanian cohort, vomiting
    was the most common presenting symptom at 57.1%.

    '
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:38344522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vomiting was the most prevalent symptom (57.1%), and encephalopathy occurred in 33.3%.
    explanation: Directly quantifies vomiting as the most common symptom.
- name: Encephalopathy
  frequency: FREQUENT
  description: 'Acute encephalopathy occurs during severe metabolic crises, mediated by hyperammonemia, direct organic acid
    neurotoxicity, and impaired neuronal energy metabolism. In a Jordanian cohort, encephalopathy occurred in 33.3%.

    '
  phenotype_term:
    preferred_term: Acute encephalopathy
    term:
      id: HP:0006846
      label: Acute encephalopathy
  evidence:
  - reference: PMID:38344522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vomiting was the most prevalent symptom (57.1%), and encephalopathy occurred in 33.3%.
    explanation: Directly quantifies encephalopathy at 33.3% in an IVA cohort.
  - reference: PMID:19210957
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Patients affected by IVAcidemia suffer from acute episodes of encephalopathy, whose underlying mechanisms are
      poorly known.
    explanation: Confirms encephalopathy as a recognized acute manifestation of IVA.
- name: Lethargy
  frequency: FREQUENT
  description: 'Reduced alertness and responsiveness during acute metabolic decompensation, ranging from somnolence to coma.

    '
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 'classic' organic acidaemias (OAs) (propionic, methylmalonic and isovaleric) typically present in neonates
      or infants as acute metabolic decompensation with encephalopathy.
    explanation: Acute metabolic decompensation with encephalopathy encompasses lethargy as a presenting feature.
- name: Hypoglycemia
  frequency: OCCASIONAL
  description: 'Hypoglycemia may occur during metabolic crises, reported in 14.3% of patients in a Jordanian cohort.

    '
  phenotype_term:
    preferred_term: Hypoglycemia
    term:
      id: HP:0001943
      label: Hypoglycemia
  evidence:
  - reference: PMID:38344522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Laboratory results showed acidosis (81%), hyperammonemia (71.4%), and hypoglycemia (14.3%).
    explanation: Directly quantifies hypoglycemia at 14.3% in an IVA cohort.
- name: Seizures
  frequency: OCCASIONAL
  description: 'Seizures may occur during severe metabolic decompensation, likely mediated by hyperammonemia and direct neurotoxicity
    of accumulated metabolites.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This is frequently accompanied by severe hyperammonaemia and constitutes a metabolic emergency, as increased
      ammonia levels and accumulating toxic metabolites are associated with life-threatening neurological complications.
    explanation: Severe neurological complications from hyperammonemia include seizures during metabolic crises.
- name: Global developmental delay
  frequency: OCCASIONAL
  description: 'Developmental delay is a risk in severe or recurrent disease, particularly following repeated hyperammonemic
    episodes.

    '
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Repeated and frequent episodes of hyperammonaemia (alongside metabolic decompensations) can result in impaired
      growth and intellectual disability, the severity of which increase with longer duration of hyperammonaemia.
    explanation: Supports developmental compromise from repeated hyperammonemic episodes.
- name: Intellectual disability
  frequency: OCCASIONAL
  description: 'Intellectual disability may develop as a long-term consequence of recurrent metabolic crises and hyperammonemia,
    particularly in severe neonatal-onset forms.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Repeated and frequent episodes of hyperammonaemia (alongside metabolic decompensations) can result in impaired
      growth and intellectual disability, the severity of which increase with longer duration of hyperammonaemia.
    explanation: Directly supports intellectual disability as outcome of repeated hyperammonemic episodes in organic acidaemias.
- name: Failure to thrive
  frequency: OCCASIONAL
  description: 'Growth impairment can occur in patients with recurrent or poorly controlled disease due to chronic metabolic
    instability and dietary protein restriction.

    '
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Repeated and frequent episodes of hyperammonaemia (alongside metabolic decompensations) can result in impaired
      growth and intellectual disability
    explanation: Supports impaired growth as a consequence of recurrent metabolic instability.
- name: Pancytopenia
  frequency: OCCASIONAL
  description: 'Pancytopenia and neutropenia may occur during acute metabolic decompensation in organic acidemias including
    IVA, due to bone marrow suppression by toxic metabolites.

    '
  phenotype_term:
    preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  notes: Pancytopenia may occur during severe metabolic decompensation in organic acidemias, but this entry currently lacks a direct abstract quote explicitly naming pancytopenia in IVA.
- name: Characteristic sweaty feet odor
  frequency: FREQUENT
  description: 'A distinctive sweaty feet or cheesy odor due to volatile isovaleric acid accumulation is a classic clinical
    feature of IVA, particularly during acute metabolic crises.

    '
  phenotype_term:
    preferred_term: Body odor
    term:
      id: HP:0500001
      label: Body odor
  evidence:
  - reference: PMID:27613073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among these disorders, methyl malonic aciduria, propionic aciduria, maple syrup urine disease and isovaleric
      aciduria are sometimes referred to as classical organic acidurias.
    explanation: IVA is a classical organic aciduria characterized by distinct volatile acid accumulation producing the sweaty
      feet odor.
biochemical:
- name: Isovalerylcarnitine (C5)
  presence: INCREASED
  context: 'Elevated C5 acylcarnitine in blood is the primary newborn screening biomarker for IVA. However, standard NBS measures
    the sum of all C5 isomers and isobars, creating false positives from pivaloylcarnitine when mothers receive pivaloylester-containing
    antibiotics.

    '
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency
      of isovaleryl-CoA dehydrogenase (IVD), leading to an accumulation of isovaleric acid and its derivates 3-hydroxyisovaleric
      acid, isovaleryl (C5)-carnitine and isovalerylglycine in body fluids.
    explanation: Directly supports elevated C5 carnitine as a characteristic IVA biomarker.
  - reference: PMID:36636590
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Newborn screening (NBS) for isovaleric acidemia (IVA) is performed by flow injection tandem mass spectrometry
      quantifying C5 carnitines (C5).
    explanation: Confirms C5 as the primary NBS analyte for IVA detection.
- name: Isovalerylglycine
  presence: INCREASED
  context: 'Urinary isovalerylglycine is a pathognomonic biomarker for IVA, formed by glycine conjugation of isovaleryl-CoA
    primarily via GLYAT and GLYATL1 in the liver. It is a key confirmatory marker in urine organic acid analysis.

    '
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency
      of isovaleryl-CoA dehydrogenase (IVD), leading to an accumulation of isovaleric acid and its derivates 3-hydroxyisovaleric
      acid, isovaleryl (C5)-carnitine and isovalerylglycine in body fluids.
    explanation: Directly supports isovalerylglycine as a characteristic accumulated metabolite.
  - reference: PMID:36817957
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: GLYAT forms part of the phase II glycine conjugation pathway in the liver and detoxifies excess acyl-CoA's namely
      benzoyl-CoA.
    explanation: Supports GLYAT-mediated glycine conjugation as the source of isovalerylglycine.
- name: 3-Hydroxyisovaleric acid
  presence: INCREASED
  context: 'Elevated 3-hydroxyisovaleric acid in urine organic acid analysis is a characteristic biomarker for IVA and one
    of the key confirmatory analytes alongside isovalerylglycine.

    '
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency
      of isovaleryl-CoA dehydrogenase (IVD), leading to an accumulation of isovaleric acid and its derivates 3-hydroxyisovaleric
      acid, isovaleryl (C5)-carnitine and isovalerylglycine in body fluids.
    explanation: Directly lists 3-hydroxyisovaleric acid as one of the accumulated metabolites.
- name: Isovaleric acid
  presence: INCREASED
  context: 'Free isovaleric acid is the proximal toxic metabolite in IVA. Its volatile nature produces the characteristic
    sweaty feet odor. Isovaleric acid contributes to neurotoxicity through inhibition of Na+,K+-ATPase and TCA cycle enzymes
    in brain tissue.

    '
  evidence:
  - reference: PMID:19210957
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Isovaleric acidemia (IVAcidemia) is an inborn error of metabolism due to deficiency of isovaleryl-CoA dehydrogenase
      activity, leading to predominant accumulation of isovaleric acid (IVA).
    explanation: Supports isovaleric acid as the predominant accumulated metabolite.
- name: Ammonia
  presence: INCREASED
  context: 'Hyperammonemia is a secondary biochemical finding during acute metabolic crises, resulting from inhibition of
    NAGS by isovaleryl-CoA and consequent urea cycle impairment.

    '
  evidence:
  - reference: PMID:38344522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Laboratory results showed acidosis (81%), hyperammonemia (71.4%), and hypoglycemia (14.3%).
    explanation: Directly quantifies hyperammonemia frequency in an IVA cohort.
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This is frequently accompanied by severe hyperammonaemia and constitutes a metabolic emergency
    explanation: Supports hyperammonemia as a frequent finding in classic organic acidaemias.
- name: Free carnitine
  presence: DECREASED
  context: 'Secondary carnitine deficiency results from increased conjugation of carnitine with isovaleryl-CoA to form isovalerylcarnitine,
    depleting free carnitine stores.

    '
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of a protein-restricted diet combined with supplementation of carnitine and/or glycine and
      emergency treatment in catabolic episodes.
    explanation: Carnitine supplementation requirement implies secondary carnitine depletion.
genetic:
- name: IVD variants
  gene_term:
    preferred_term: IVD
    term:
      id: hgnc:6186
      label: IVD
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:41133704
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency
        of isovaleryl-CoA dehydrogenase (IVD)
      explanation: Supports inherited Mendelian etiology consistent with autosomal recessive inheritance.
  variants:
  - name: IVD - c.941C>T (p.Ala314Val) - mild IVA variant
    description: 'The c.941C>T (p.Ala314Val) variant in IVD is commonly associated with the attenuated or mild biochemical
      phenotype detected by newborn screening. Individuals homozygous for this variant may remain clinically asymptomatic.

      '
    evidence:
    - reference: PMID:36837923
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: NBS for IVA is hampered by, first, the increased birth prevalence due to the identification of individuals
        with an attenuated disease variant (so-called "mild" IVA)
      explanation: Supports existence of attenuated IVA variants detected by newborn screening.
  - name: Various pathogenic IVD variants
    description: 'Multiple pathogenic variants in IVD have been described causing variable clinical severity from severe neonatal-onset
      to chronic intermittent forms. Biallelic pathogenic variants are required for disease manifestation.

      '
    evidence:
    - reference: PMID:41133704
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency
        of isovaleryl-CoA dehydrogenase (IVD)
      explanation: Supports IVD as the causal gene with biallelic variants required.
  features: 'Biallelic pathogenic variants in IVD cause variable phenotypic severity spanning severe neonatal-onset acute
    metabolic crises to mild biochemical-only phenotypes identified through newborn screening. The IVD gene encodes a mitochondrial
    flavoprotein that catalyzes the conversion of isovaleryl-CoA to 3-methylcrotonyl-CoA in the leucine catabolic pathway.

    '
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency
      of isovaleryl-CoA dehydrogenase (IVD), leading to an accumulation of isovaleric acid and its derivates 3-hydroxyisovaleric
      acid, isovaleryl (C5)-carnitine and isovalerylglycine in body fluids.
    explanation: Directly supports IVD as the causal gene with characteristic metabolite accumulation.
  - reference: PMID:27613073
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among these disorders, methyl malonic aciduria, propionic aciduria, maple syrup urine disease and isovaleric
      aciduria are sometimes referred to as classical organic acidurias.
    explanation: Supports IVA as a classical organic aciduria with well-defined genetic basis.
treatments:
- name: Leucine-restricted diet
  description: 'Protein-restricted or leucine-restricted dietary management with specialized metabolic formula is the cornerstone
    of chronic IVA management. The goal is to reduce leucine flux and thereby limit isovaleryl-CoA production.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of a protein-restricted diet combined with supplementation of carnitine and/or glycine and
      emergency treatment in catabolic episodes.
    explanation: Directly supports protein-restricted diet as the primary chronic treatment.
  - reference: PMID:38344522
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The early initiation of treatment for organic acid disorders carries a more favorable prognosis.
    explanation: Supports early treatment initiation including dietary management for better outcomes.
- name: L-Carnitine supplementation
  description: 'L-carnitine supplementation promotes formation and urinary excretion of isovalerylcarnitine, reducing the
    toxic free isovaleric acid pool and correcting secondary carnitine deficiency.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of a protein-restricted diet combined with supplementation of carnitine and/or glycine and
      emergency treatment in catabolic episodes.
    explanation: Directly supports carnitine supplementation as part of standard IVA treatment.
- name: Glycine supplementation
  description: 'Glycine supplementation promotes conjugation of isovaleryl-CoA to isovalerylglycine, a less toxic water-soluble
    metabolite excreted in urine. However, glycine supplementation should be carefully considered as increased glycine concentration
    does not proportionally increase N-isovalerylglycine formation.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of a protein-restricted diet combined with supplementation of carnitine and/or glycine and
      emergency treatment in catabolic episodes.
    explanation: Directly supports glycine supplementation as part of standard treatment.
- name: N-Carbamylglutamate (carglumic acid)
  description: 'N-carbamylglutamate is a synthetic analog of N-acetylglutamate approved for treatment of hyperammonemia in
    IVA. It directly activates CPS1, bypassing the NAGS inhibition caused by isovaleryl-CoA, and can rapidly normalize ammonia
    levels.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment with N-carbamyl-L-glutamate can rapidly normalise ammonia levels by stimulating the first step of the
      urea cycle.
    explanation: Directly supports N-carbamylglutamate as an effective treatment for hyperammonemia in organic acidaemias.
- name: Acute decompensation management
  description: 'Emergency management during catabolic crises includes cessation of protein intake, high-calorie glucose infusion
    to reverse catabolism, correction of metabolic acidosis, and administration of ammonia scavengers when needed.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of a protein-restricted diet combined with supplementation of carnitine and/or glycine and
      emergency treatment in catabolic episodes.
    explanation: Directly supports emergency treatment during catabolic episodes.
  - reference: PMID:30522498
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The acute management of hyperammonaemia in organic acidaemias requires administration of intravenous calories
      as glucose and lipids to promote anabolism, carnitine to promote urinary excretion of urinary organic acid esters, and
      correction of metabolic acidosis
    explanation: Provides detailed acute management protocol for hyperammonemia in organic acidaemias.
- name: Newborn screening
  description: 'IVA is detectable by newborn screening via tandem mass spectrometry measuring C5 acylcarnitines. However,
    false positives from pivaloylcarnitine are an increasing problem, and second-tier chromatographic methods are needed to
    differentiate C5 isomers.

    '
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:36636590
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Out of 156 772 newborns tested, one turned out to have genetically proven IVA while 99 were false positive (C5:
      0.5-8.2 Î¼mol/L) due to the presence of pivaloylcarnitine.'
    explanation: Documents NBS implementation and the high false-positive rate from pivaloylcarnitine interference.
  - reference: PMID:36837923
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: Our results show that this reduces the false positive rate by 69.9% from 103 to 31 while maintaining 100% sensitivity
      in cross-validation.
    explanation: Demonstrates machine learning approach to improve NBS specificity for IVA.
- name: Genetic counseling
  description: 'Genetic counseling for affected families includes discussion of autosomal recessive inheritance, 25% recurrence
    risk, carrier testing for relatives, prenatal diagnosis options, and distinction between severe and mild IVA genotypes.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:41133704
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency
      of isovaleryl-CoA dehydrogenase (IVD)
    explanation: Inherited genetic etiology supports the role of genetic counseling for affected families.
notes: 'The clinical spectrum of IVA has broadened with the introduction of newborn screening, which detects many individuals
  with attenuated biochemical phenotypes (mild IVA) who may never develop clinical symptoms. This has raised questions about
  potential overdiagnosis and overtreatment. A major practical challenge in NBS is the false-positive rate from pivaloylcarnitine,
  which is isobaric with isovalerylcarnitine. Second-tier chromatographic methods and machine learning approaches are being
  implemented to improve screening specificity. Glycine conjugation via GLYAT and GLYATL1 represents a key detoxification
  pathway, though 2023 evidence suggests the enzyme kinetics limit the benefit of simply increasing glycine supplementation.

  '
